Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?

被引：3

作者：

Abdul-Ghani, Muhammad ^{[1
]}

Jayyous, Amin ^{[1
]}

Asaad, Nidal ^{[2
]}

Helmy, Sherif ^{[2
]}

Al-Suwaidi, Jassim ^{[2
]}

机构：

[1] Hamad Gen Hosp, Acad Hlth Syst, POB 3050, Doha, Qatar

[2] Hamad Gen Hosp, Cardiometab Inst, Doha, Qatar

来源：

ANNALS OF TRANSLATIONAL MEDICINE | 2018年 / 6卷 / 10期

关键词：

TYPE-2; DIABETES-MELLITUS; MICROVASCULAR COMPLICATIONS; INSULIN-RESISTANCE; GLYCEMIC CONTROL; BLOOD-PRESSURE; PREVENTION; DISEASE; THERAPY; EVENTS; ATHEROSCLEROSIS;

D O I：

10.21037/atm.2018.03.19

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：5

共 50 条

[1] Risk of cardiovascular disease in patients with T2DM
Nature Reviews Endocrinology, 2013, 9 (6) : 316 - 316
[2] Pioglitazone: no increased risk of bladder cancer with T2DM
Reactions Weekly, 2017, 1668 (1) : 10 - 10
[3] Pioglitazone safe and effective for treating T2DM in patients with NASH
Tim Geach
Nature Reviews Endocrinology, 2016, 12 (9) : 498 - 498
[4] Dapagliflozine is now available for patients with T2DM (cardiovascular and/or renal risk)
Blond, Brigitte
CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2020, 24 (03): : 119 - 119
[5] Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM
Nada, Aml Mohamed
Younan, Mariam Adel
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2021, 12
[6] INSOMNIA AND T2DM ON CARDIOVASCULAR RISK PERCEPTION IN MENOPAUSE
Okun, Michele L.
Feliciano, Leilani
Johanson, Kathrine
Schneider, Lauren M.
Prue-Owens, Kathy
PSYCHOSOMATIC MEDICINE, 2018, 80 (03): : A15 - A15
[7] Pioglitazone, but not rosiglitazone, suppressess De Novo lipogenesis (DNL) in patients with T2DM
Beysen, Carine
Nagaraja, H.
Murphy, Elizabeth
Riiff, Tim
Yen, Erica
Hellerstein, Marc
Boyle, Patrick
DIABETES, 2006, 55 : A62 - A62
[8] Pioglitazone (PIO) enhances insulin sensitivity (IS) in patients with type 2 diabetes (T2DM)
Johns, D
Herz, M
Tan, MH
Robertson, KE
Gonzalez, B
Reviriego, J
Grossman, LD
DIABETES, 2002, 51 : A102 - A102
[9] Cardiovascular safety of dapagliflozin in type 2 diabetes mellitus (T2DM) patients with various degrees of cardiovascular risk
Sonesson, C.
Frederich, R.
Johansson, P. A.
Gause-Nilsson, I.
Langkilde, A. M.
List, J. F.
EUROPEAN HEART JOURNAL, 2014, 35 : 1072 - 1072
[10] Insulin signaling regulating genes: effect on T2DM and cardiovascular risk
Prudente, Sabrina
Morini, Eleonora
Trischitta, Vincenzo
NATURE REVIEWS ENDOCRINOLOGY, 2009, 5 (12) : 682 - 693

← 1 2 3 4 5 →